clofibrate has been researched along with Kidney Diseases in 17 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clofibrate treatment attenuated kidney damage and hepatic oxidative stress while maintaining serum/hepatic sulfatide levels and hepatic CST content in the mice." | 1.38 | Attenuation of kidney injuries maintains serum sulfatide levels dependent on hepatic synthetic ability: a possible involvement of oxidative stress. ( Aoyama, T; Hara, A; Kamijo, Y; Kyogashima, M; Nakajima, T; Sheng, X; Sugiyama, E; Takahashi, K; Tanaka, N; Wang, L; Zhang, X, 2012) |
| " It is concluded that, from a pharmacokinetic point of view, a reduction in the dosage of ciprofibrate should be considered in patients with a glomerular filtration rate below 30 ml min-1/1." | 1.28 | The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate. ( Bernard, N; Cuisinaud, G; Ferry, N; Gardes, E; Labeeuw, M; Pozet, N; Sassard, J; Zech, PY, 1989) |
| "Treatment with clofibrate is known to increase drastically the number of peroxisomes in mammalian liver." | 1.27 | Unsuccessful attempts to induce peroxisomes in two cases of Zellweger disease by treatment with clofibrate. ( Björkhem, I; Blomstrand, S; Glaumann, H; Strandvik, B, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (88.24) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gelosa, P | 1 |
| Banfi, C | 1 |
| Gianella, A | 1 |
| Brioschi, M | 1 |
| Pignieri, A | 1 |
| Nobili, E | 1 |
| Castiglioni, L | 1 |
| Cimino, M | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Sheng, X | 1 |
| Nakajima, T | 1 |
| Wang, L | 1 |
| Zhang, X | 1 |
| Kamijo, Y | 1 |
| Takahashi, K | 1 |
| Tanaka, N | 1 |
| Sugiyama, E | 1 |
| Kyogashima, M | 1 |
| Aoyama, T | 1 |
| Hara, A | 1 |
| Birgens, HS | 1 |
| Hansen, MS | 1 |
| Abshagen, U | 1 |
| Kösters, W | 1 |
| Kaufmann, B | 1 |
| Lang, PD | 1 |
| Bianchi, V | 1 |
| Bertoli, D | 1 |
| Barbanti, M | 1 |
| Mazzoni, M | 1 |
| Bortolan, S | 1 |
| Rosa, P | 1 |
| Martines, G | 1 |
| Pierce, EH | 1 |
| Chesler, DL | 1 |
| Harker, LA | 1 |
| Hirsh, J | 1 |
| Gent, M | 1 |
| Genton, E | 1 |
| Weiss, HJ | 1 |
| Curtis, JR | 1 |
| Rumpf, KW | 1 |
| Quellhrost, E | 1 |
| Scheler, F | 1 |
| Ferry, N | 1 |
| Bernard, N | 1 |
| Pozet, N | 1 |
| Gardes, E | 1 |
| Cuisinaud, G | 1 |
| Labeeuw, M | 1 |
| Zech, PY | 1 |
| Sassard, J | 1 |
| Cayen, MN | 1 |
| Björkhem, I | 1 |
| Blomstrand, S | 1 |
| Glaumann, H | 1 |
| Strandvik, B | 1 |
| Parker, F | 1 |
| De Sousa, RC | 1 |
| Petitpierre, B | 1 |
| Perrin, L | 1 |
| Rudhardt, M | 1 |
| Herrera, A | 1 |
| Fabre, J | 1 |
5 reviews available for clofibrate and Kidney Diseases
| Article | Year |
|---|---|
[Prevention of thrombosis by thrombocyte inhibition. 2. Clinical results].
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofibrate; Dextrans; | 1980 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Brain; Clofibrate; Dextrans; Dipyridamole; Humans; Ischemi | 1976 |
Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man.
Topics: Animals; Binding Sites; Biological Availability; Biotransformation; Clofibrate; Drug Interactions; H | 1985 |
[Diabetes insipidus--various recent aspects].
Topics: Animals; Arginine; Carbamazepine; Chlorpropamide; Clofibrate; Cyclic AMP; Diabetes Insipidus; Hypoth | 1974 |
1 trial available for clofibrate and Kidney Diseases
| Article | Year |
|---|---|
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
12 other studies available for clofibrate and Kidney Diseases
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; | 2010 |
Attenuation of kidney injuries maintains serum sulfatide levels dependent on hepatic synthetic ability: a possible involvement of oxidative stress.
Topics: Acute Disease; Animals; Clofibrate; Disease Models, Animal; Drug Antagonism; Female; Gene Expression | 2012 |
Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Kidney | 1980 |
[Effects of clofibrate on rabbit kidneys].
Topics: Animals; Clofibrate; Kidney; Kidney Diseases; Lipids; Male; Rabbits | 1980 |
[Selective lipid therapy].
Topics: Arteriosclerosis; Clofibrate; Hyperlipidemias; Kidney Diseases; Lipoproteins | 1978 |
Possible association of granulomatous hepatitis with clofibrate therapy.
Topics: Aged; Chemical and Drug Induced Liver Injury; Clofibrate; Female; Granuloma; Humans; Kidney Diseases | 1978 |
Diseases of the urinary system. Drug-induced renal disorders: I.
Topics: Aminoglycosides; Anesthetics; Anti-Bacterial Agents; Anticoagulants; Clofibrate; Contrast Media; Hum | 1977 |
[Diabetic nephropathy, hypothyroidism and colfibrate-induced myopathy (author's transl)].
Topics: Adult; Clofibrate; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabet | 1976 |
The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
Topics: Adult; Aged; Clofibrate; Clofibric Acid; Female; Fibric Acids; Humans; Hypolipidemic Agents; Kidney | 1989 |
Unsuccessful attempts to induce peroxisomes in two cases of Zellweger disease by treatment with clofibrate.
Topics: Abnormalities, Multiple; Brain Diseases; Clofibrate; Female; Humans; Infant; Kidney Diseases; Liver | 1985 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr | 1985 |
Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.
Topics: Acenocoumarol; Allopurinol; Chloramphenicol; Chlorpropamide; Clofibrate; Glomerular Filtration Rate; | 1972 |